AlphAIalphai — Financial news for AI agents
scanx.tradeJUL 294 min read$MNKD

MannKind Q2 Results: Financial data release set for August 5

MannKind Corporation (NASDAQ: MNKD) said it will release Q2 2026 financial results after the market close on Aug. 5, 2026. A conference call is scheduled for 4:30 p.m. ET with a webcast and replay on the company’s investor site. The article also notes a Breakthrough T1D grant supporting the INHALE-1ST Afrezza study in pediatric type 1 diabetes.

Original reporting
scanx.trade
Published Jul 29, 2026, 12:12 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 2:47 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
MannKind Q2 Results: Financial data release set for August 5 — source image
Source · scanx.trade
Decision brief

The 30-second read

$MNKDNeutralMed
01

Why it matters

The key tradable event is the confirmed Aug 5 after-hours Q2 results and the same-day call, which can reprice expectations. The Breakthrough T1D grant provides supportive context for the pediatric program but does not substitute for efficacy or regulatory milestones.

02

Market read

This is a pre-earnings procedural notice with an added clinical-support detail, making it more useful for event positioning than for fundamental repricing today.

03

What to watch

Traders should focus on what management discloses on Aug 5: Afrezza commercial trajectory, pipeline timelines, and any updates on INHALE-1ST enrollment, safety, or interim signals.

Relevance 5/10Novelty 4/10Timing: Ahead of Aug 5 after-hours Q2 earnings release and 4:30 p.m. ET conference call.

Background

MannKind is a biopharmaceutical company developing and commercializing Afrezza (inhaled insulin) and running pediatric-focused clinical work via INHALE-1ST.

Company-level read

Ticker impact

$MNKDNeutralMedium confidence
Context

MannKind schedules Q2 2026 results for Aug 5 after market close and notes Breakthrough T1D grant support for INHALE-1ST Afrezza pediatric study.

Expected impact

Likely limited pre-earnings drift; bigger move risk on Aug 5 depending on revenue, margins, and any Afrezza pediatric program updates.

Evidence & confidence

The article provides a confirmed reporting timeline (actionable for positioning) but no new financial numbers. The Breakthrough T1D grant is supportive yet not a definitive efficacy or regulatory milestone, so impact is likely secondary versus the earnings print.

Market effects

Sector

Highlights ongoing investment and clinical development momentum in inhaled insulin and pediatric diabetes care within biopharma.

Regional

No specific regional market linkage beyond US-listed biotech earnings timing.

Global

Breakthrough T1D is global; pediatric diabetes development themes can influence broader investor sentiment toward diabetes therapeutics.

Counterpoint

What could challenge this read

The Breakthrough T1D grant may be incremental and already expected; without new trial readouts or regulatory actions, it may not change valuation materially.

Key entities

  • company
    MannKind Corporation

    NASDAQ-listed biopharmaceutical company scheduled to report Q2 2026 results on Aug 5 and running INHALE-1ST for Afrezza in newly diagnosed pediatric type 1 diabetes.

  • product
    Afrezza

    MannKind inhalation powder insulin used in the INHALE-1ST trial regimen.

  • clinical_trial
    INHALE-1ST

    Multi-center single-arm study assessing Afrezza plus once-daily basal insulin in youth aged 10 to <18 with newly diagnosed type 1 diabetes.

  • organization
    Breakthrough T1D

    Provides a grant via its IDDP program to support the INHALE-1ST clinical study.

Read at source← All news

Related articles

AUG 5
$MNKDMedAI 8/10

MANNKIND CORP (MNKD): Results of Operations and Financial Condition

MANNKIND CORP (MNKD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mnkd-ex99_1.htm EX-99.1 EX-99.1 MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update • Achieved three major catalysts to drive future growth: o Launched the pediatric indication of Afrezza ® following FDA approval o FUROSCIX ReadyFlow™ aut

SEC EDGAR 8-K4 min
JUL 29
$MNKDMed

MannKind's Nintedanib DPI Shows Favorable Safety In IPF Patients

MannKind (MNKD) reported positive topline Phase 1b INFLO-1 results for nintedanib dry powder inhalation in idiopathic pulmonary fibrosis. In a randomized, double-blind, placebo-controlled trial of 27 patients, it met the primary objective of safety and tolerability, with no serious adverse events, GI effects, bronchospasm, or discontinuations. MannKind is enrolling Phase 2 INFLO-2.

rttnews.com4 min
JUL 29
$MNKDMedAI 8/10

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

MannKind (Nasdaq: MNKD) reported positive topline Phase 1b INFLO-1 results for nintedanib dry powder inhalation (DPI) in idiopathic pulmonary fibrosis. In 27 patients, it met safety and tolerability goals with no serious adverse events, no bronchospasm or diarrhea, and no discontinuations. Phase 2 INFLO-2 is enrolling about 210 patients.

finanznachrichten.de3 min
JUL 24
$MNKDMedAI 8/10

FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease - MannKind (NASDAQ:M

The FDA approved MannKind’s Furoscix ReadyFlow, a furosemide injection autoinjector for edema in adults with heart failure or chronic kidney disease. MannKind said it delivers an 80 mg/mL dose in under 10 seconds. The company also announced a private placement of about $50 million to fund general purposes, including a $45 million contingent value rights payment. MNKD shares rose to about $4.16.

benzinga.com4 min